1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Roche Powers Forward With First-Line Tecentriq In Advanced NSCLC

 
• By John Davis

The actual data on the clinically meaningful effect on PFS of the triple combination of Tecentriq, Avastin and chemotherapy on previously untreated advanced NSCLC patients in the IMpower150 study have now been presented at a scientific meeting, and suggest that Roche could be a significant competitor in the large NSCLC market in the not too distant future.

Lungs
• Source: Shutterstock

Roche's PD-L1 inhibitor Tecentriq (atezolizumab) was associated with a 38% reduction in the risk of disease worsening or death when used as part of a chemotherapy regimen for previously untreated advanced non-squamous non-small cell lung cancer in the IMpower150 study, the company announced on Dec. 7. This puts a concrete figure on last month's announcement that the Tecentriq combination had provided a statistically significant and clinically meaningful reduction in progression-free survival (PFS).

The IMpower150 study is the "first positive Phase III combination trial showing a cancer immunotherapy reduced the risk of worsening disease when used as an initial treatment in a broad group of people with advanced non-squamous NSCLC," Roche noted. The company's share price initially rose by nearly 10% on Dec

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.